Results 191 to 200 of about 39,721 (242)

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

Lancet, The, 1999
BACKGROUND The AIDS Clinical Trials Group protocol 076 zidovudine prophylaxis regimen for HIV-1-infected pregnant women and their babies has been associated with a significant decrease in vertical HIV-1 transmission in non-breastfeeding women in ...
Danstan Bagenda, Paul M Bakaki, J Brooks Jackson   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019
Dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine are antiretroviral drugs used as part of combined antiretroviral treatment for HIV-infection.
P. Bollen, M. de Graaff-Teulen, S. Schalkwijk, N. V. van Erp, D. Burger   +4 more
semanticscholar   +1 more source

Nevirapine Hypersensitivity

2009
Treatment of HIV-1 infections with nevirapine is associated with skin and liver toxicity. These two organ toxicities range from mild to severe, in rare cases resulting in life-threatening liver failure or toxic epidermal necrolysis. The study of the mechanistic steps leading to nevirapine-induced skin rash has been facilitated by the discovery of an ...
M, Popovic, J M, Shenton, J, Chen, A, Baban, T, Tharmanathan, B, Mannargudi, D, Abdulla, J P, Uetrecht   +7 more
openaire   +2 more sources

Improving antiproliferative effect of the nevirapine on Hela cells by loading onto chitosan coated magnetic nanoparticles as a fully biocompatible nano drug carrier.

International Journal of Biological Macromolecules, 2018
The freshly prepared magnetic iron oxide nanoparticles (MIONPs) were coated with SiO2 and then modified with a Si-based linker (SiL) having chlorine atom at the end of its chain.
Neda Hosseinpour Moghadam, S. Salehzadeh, Jamshid Rakhtshah, Hamid Tanzadehpanah, A. Moghadam, Farshid Hajibabaei, S. Sharifinia, S. S. Asl, M. Saidijam   +8 more
semanticscholar   +1 more source

Formulation and characterization of cellulose acetate butyrate nanoparticles loaded with nevirapine for HIV treatment

Journal of Drug Delivery Science and Technology, 2018
The aim of this study was development of polymeric NPs for efficient macrophage delivery of nevirapine for treatment of AIDS. Emulsification solvent evaporation method was employed to fabricate cellulose acetate butyrate (CAB) NPs containing nevirapine ...
J. Varshosaz, Somayeh Taymouri, E. Jafari, A. Jahanian-Najafabadi, Azade Taheri   +4 more
semanticscholar   +1 more source

Nevirapine toxicity

International Journal of STD & AIDS, 2006
The number of HIV-infected patients who are newly exposed to nevirapine is increasing worldwide. To minimize toxicity, clinicians must adhere to dosing guidelines, avoid prescribing the drug in patients with known increased risk of toxicity, and promptly recognize toxicities, which are mainly cutaneous and hepatic.
openaire   +2 more sources

Effect of long-term administration of antiretroviral drugs (Tenofovir and Nevirapine) on neuroinflammation and neuroplasticity in mouse hippocampi.

Journal of Chemical Neuroanatomy, 2018
The use of combination antiretroviral therapy (cART) has been successful in suppressing HIV-1 replication and restoring peripheral immune functioning in HIV-infected individuals. Despite these advances in the management of HIV, neurocognitive impairments
S. Zulu, N. Simola, M. Mabandla, W. Daniels   +3 more
semanticscholar   +1 more source

Nevirapine

Reactions Weekly, 2007
David Asmuth, Richard Pollard
  +6 more sources

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

Lancet, The, 2004
F. V. Leth, P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller, B. Gazzard, P. Cahn, U. Lalloo, IP van der Westhuizen, Malan*, Margaret A. Johnson, B. Santos, F. Mulcahy, R. Wood, GC Levi, G. Reboredo, K. Squires, I. Cassetti, D. Petit, F. Raffi, C. Katlama, R. Murphy, A. Horban, J. Dam, E. Hassink, R. V. Leeuwen, P. Robinson, F. Wit, J. Lange   +28 more
exaly   +2 more sources